No Data
Volume change rate ranking (9 o'clock) ~ BASE, Kochi Bank, etc. ranked in.
In the volume change rate ranking, you can understand the interests of market participants such as trends in speculation by comparing the volume of the latest 5 days on average with the volume on the day of delivery. Top Volume Change Rate [As of 9:32 on November 7] (Compared to the average volume of the latest 5 days) Stock Code Stock Name Volume 5-day Average Volume Volume Change Rate Price Change Rate <6177> AppBank 222,780 107,185 108.74% 0.0645% <6518>
Slogan: Transcript of financial results briefing for the 2nd quarter of the fiscal year ending 2025/2
Stocks that moved the previous day part2: J-DEP ADVANCE, Kave, Metaplanet, etc.
Stock name <Code> Closing price on the 15th ⇒ Day-on-day comparison Beewise <9216> 1679 -139 Negative view on the sharp decline in operating profit in the first quarter results. Osaka Organic Chemical Industry <4187> 3100 -1756- Operating profit decline is expected to widen in August. Sansan <4443> 2166 -59 Limited positive impact on the financial results. ENEOS <5020> 802.5 -39.7 Petroleum stocks are generally lower due to the fall in crude oil prices. INPEX <1605> 2031.5 -68
Virginia Cancer Specialists Reveals New Brand Direction for Their Comprehensive Breast Center, Expansion of High-Risk Breast Clinic, and New Hope-Inspired Slogan in Honor of October, Breast Cancer Awareness Month
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Matsushita <9601> 9246 -106 Lowered financial estimates for the fiscal year ending March 2025. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% from the previous year and by 19.6% for the current year. Albaitai <2341> 143 -8 The operating profit for the previous term decreased by 98.2%, expanding the profit decline rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the Phase 1 trial of the CLK inhibitor CTX-712.
Active and newly established stocks in the afternoon session.
*Matsusho <9601> 9246 -106 Operating profit forecast for the fiscal year ending February 2025 revised downward. *Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% from the previous year and by 19.6% for the current year. *Alba-Tai <2341> 143 -8 Operating profit in the previous period decreased by 98.2%, expanding the decline rate from 80.3% in the first quarter. *Chordia <190A> 296 -38 Results of the phase 1 clinical trial of the CLK inhibitor CTX-712 announced at the Japanese Society of Hematology Annual Meeting. *Aer
No Data
No Data